Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

About Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer. Sponsored by Lilly

Publisher

Amplity, Inc.

Category

health & fitness · health & fitness

Language

en

Explicit

No

First episode

14 Jan 2026

Latest episode

17 Feb 2026

Latest episodes

6 episodes in the feed.

1. 

   17 Feb 2026

   Part 6: Results From OptiTROP-Breast02

   We are pleased to present Part 6, the final installment of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial. Topics include: Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug conjugate (ADC) Future direction of ADC treatments Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

2. 

   10 Feb 2026

   Part 5: Results From TACTIVE-N

   We are pleased to present Part 5 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial. Topics include: Neoadjuvant vepdegestrant: results of TACTIVE-N trial Tolerance in next-generation endocrine therapies: PROTAC estrogen receptor degraders Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

3. 

   4 Feb 2026

   Part 4: First Results From VIKTORIA-1

   We are pleased to present Part 4 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial. Topics include: Mechanisms of resistance to CDK4/6 inhibitors Rationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohort Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

4. 

   28 Jan 2026

   Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy

   We are pleased to present Part 3 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 3 of this series provides peer-to-peer physician perspectives on strategies for staying on CDK4/6 inhibitor therapy. Topics include: Clinical trial experience managing adverse events of CDK4/6 inhibitors in early breast cancer Treatment persistence during real-world adjuvant CDK4/6 inhibitor therapy Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

5. 

   21 Jan 2026

   Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence

   We are pleased to present Part 2 of an exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 2 of this series provides peer-to-peer physician perspectives on best practices in managing early breast cancer. Topics include: Best practices in treating early HR-positive/HER2-negative breast cancer with a high risk of recurrence Balancing efficacy and quality of life during maintenance endocrine therapy with adjuvant CDK4/6 inhibitor treatment Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

6. 

   14 Jan 2026

   Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer

   We are pleased to present Part 1 of an exclusive podcast, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. Part 1 of this series provides peer-to-peer physician perspectives on emerging data in the adjuvant treatment of hormone receptor (HR)-positive/HER2-negative early breast cancer. Topics include: The role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in the treatment of early-stage HR-positive/HER2-negative breast cancer Long-term outcomes of CDK4/6 inhibitors including new 7-year data from the monarchE trial and 5-year data from the NATALEE trial Discussants: Neil M. Iyengar, MD Director, Survivorship Services, Winship Cancer Institute of Emory University Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine Atlanta, GA Seth Wander, MD, PhD Director, Precision Medicine, Termeer Center for Targeted Therapies Director, Translational Research, Breast Oncology Program Assistant Professor of Medicine, Harvard Medical School Massachusetts General Hospital Boston, MA Sponsored by Lilly (https://www.lilly.com/)

Contact Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.